Domo signs strategic collaboration agreement with AWS for AI solutions
Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, today reported the outcomes of its 2025 Annual General Meeting (AGM). The AGM saw all proposed resolutions passed, with resolutions 19 through 22 approved as special resolutions and the remainder as ordinary resolutions.
The company, which specializes in products across Oral Health, Pain Relief, Vitamins, Minerals and Supplements (VMS), and other health categories, confirmed that the poll vote took place today, with the full text of the resolutions available on their website.
Significant resolutions included the re-election of board members, approval of the Directors’ Remuneration Report, declaration of a final dividend, and the re-appointment of KPMG as the company’s auditor. Additionally, the company received authorization to make political donations, purchase its own shares, and allot ordinary shares. Shareholders also granted permission to disapply pre-emption rights and authorized a 14-day notice period for general meetings.
The results reflect a high level of shareholder engagement, with over 83% of the issued share capital voted on most resolutions. The company emphasized that votes withheld are not counted in the calculation of the votes "For" or "Against" a resolution.
Haleon’s portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are underpinned by trusted science and innovation.
The company’s focus remains on delivering better everyday health with humanity, as reflected in its diverse range of consumer health products. The resolutions passed at the AGM are expected to support Haleon’s ongoing commitment to growth and shareholder value.
The details of the resolutions passed at the AGM will be made available on the National Storage Mechanism website. This announcement is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.